Background
myocarditis, cardiovascular adverse
MYOCARDITIS
Immune checkpoint inhibitors (ICIs) have revolutionized anticancer treatment and are increasingly being combined with chemotherapies or targeted therapies to enhance antitumor activity. ICIs are associated with immune-related cardiovascular adverse events (AEs), including myocarditis.